The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2101-2115

  Psyrri, A ^a   Rampias, T ^b   Vermorken, J B ^c  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cetuximab; Human papillomavirus; Oropharyngeal cancer; Panitumumab; Squamous cell carcinoma of the head and neck

Indexed keywords

AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAPATINIB; NIMORAZOLE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; SORAFENIB; TIRAPAZAMINE; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMORADIOTHERAPY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; DYSPHAGIA; FAILURE FREE SURVIVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RASH; REVIEW; SMOKING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL (TOPIC); HEAD AND NECK NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84921000018     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu265     Document Type: Review

References (83)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Gregoire V, Lefebvre JL, Licitra L et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5): v184-v186.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: head and neck cancers. Version 2.2013.
4. Hashibe M, Brennan P, Chuang S et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18: 541-550.
5. Guha N, Boffetta P, Wunsch Filho V et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric casecontrol studies. Am J Epidemiol 2007; 166: 1159-1173.
6. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
7. Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 2013; 63: 57-81.
8. Chaturvedi AK, Engels EA, Pfeiffer RM et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
9. Mehanna H, Beech T, Nicholson T et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35: 747-755.
10. Hong AM, Grulich AE, Jones D et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010; 28: 3269-3272.
11. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475.
12. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
13. Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009; 4: 49-70.
14. Rampias T, Sasaki C, Psyrri A. Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol 2014; 50(5): 356-363.
15. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
16. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101: 412-423.
17. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56: 4620-4624.
18. Cao L, Faha B, Dembski M et al. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 1992; 355: 176-179.
19. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-937.
20. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
21. Schlecht NF, Burk RD, Adrien L et al. Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007; 213: 283-293.
22. Rampias T, Pectasides E, Prasad M et al. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Ann Oncol 2013; 24: 2124-2131.
23. Hayes DN, Grandis J, El-Naggar AK. Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas. AACR Annual Meeting, Washington, DC. Abstract 1117. 7 April 2013.
24. D'Souza G, Zhang HH, D'Souza WD et al. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol 2010; 46: 100-104.
25. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
26. Hafkamp HC, Manni JJ, Haesevoets A et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008; 122: 2656-2664.
27. O'Sullivan B, Huang SH, Siu LL et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013; 31: 543-550.
28. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
29. Rischin D, Peters LJ, O'Sullivan B et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-2995.
30. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
31. Rosenthal DI, Harari PM, Giralt J et al. Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 2014; 32: abstract 6001.
32. Gillison ML, Zhang Q, Ang K et al. Analysis of the effect of p16 and tobacco packyears ( p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. J Clin Oncol 2010; 28: abstract 5510.
33. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
34. Posner MR, Lorch JH, Goloubeva O et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071-1077.
35. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
36. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998.
37. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010; 94: 30-35.
38. Overgaard J, Sand Hansen H, Overgaard M et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135-146.
39. Ang KK, Zhang QE, Rosenthal DI et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011; 29: abstract 5500.
40. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
41. Austin M, Schmidt R, Parvathaneni U et al. Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial. J Clin Oncol 2012; 30: abstract 5515.
42. Giralt J, Fortin A, Mesia R et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients ( pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2012; 30: abstract 5502.
43. Giralt J, Trigo JM, Nuyts S et al. Phase 2, randomized trial (CONCERT-2) of panitumumab (pmab) plus radiotherapy (PRT) compared with chemoradiotherapy (CRT) in patients ( pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Ann Oncol 2012; 23: abstract 1016O.
44. Egloff AM, Lee J, Vaezi AE et al. Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). J Clin Oncol 2010; 28: abstract 5537.
45. Harrington K, Berrier A, Robinson M et al. Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013; 49: 1609-1618.
46. Snietura M, Piglowski W, Jaworska M et al. Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. Eur Arch Otorhinolaryngol 2011; 268: 721-726.
47. Gilbert J, Murphy B, Dietrich MS et al. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer 2012; 118: 1007-1013.
48. Jo S, Juhasz A, Zhang K et al. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 2009; 29: 1467-1474.
49. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14.
50. Argiris A, Heron DE, Smith RP et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010; 28: 5294-5300.
51. Harrington KJ, Temam S, D'Cruz A et al. Final analysis: a randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2014; 32: abstract 6005.
52. Fakhry C, Zhang Q, Nguyen-Tan P et al. Human papillomavirus (HPV) and overall survival (OS) after progression of oropharyngeal squamous cell carcinoma (OPSCC). Int J Rad Oncol Biol Phys 2014; 88(2): 466.
53. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
54. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
55. Huang SH, Perez-Ordonez B, Weinreb I et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013; 49: 79-85.
56. Smeets SJ, Hesselink AT, Speel EJ et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121(11): 2465-2472.
57. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
58. Psyrri A, Licitra L, De Blas B et al. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial. Ann Oncol 2012; 23: abstract 1018O.
59. Vermorken JB. EXTREME (PF+/-cetuximab) and SPECTRUM (PF+/-panitumumab): HPV status and outcome. Radiother Oncol 2013; 107: abstract SP-006.
60. Vermorken JB, Psyrri A, Mesia R et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014; 25(4): 801-807.
61. Vermorken JB, Stöhlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14: 697-710.
62. Mehra R. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013; 31: abstract 6006.
63. Seiwert T, Fayette J, Cupissol D et al. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck-final data. Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ, 2012. Abstract LBPV10.
64. Wirth LJ, Dakhil RS, Kornek G et al. PARTNER: a randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab ( pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013; 31: abstract 6029.
65. Gilbert J, Schell MJ, Zhao X et al. Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2013; 31: abstract 6047.
66. Audet ML, Allo G, Weng X et al. Evaluation of potential predictive markers of efficacy of dacomitinib in patients ( pts) with recurrent/metastatic SCCHN from a phase II trial. J Clin Oncol 2013; 31: abstract 6041.
67. Chung CH, Zhang Q, Kong C et al. p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). J Clin Oncol 2013; 31: abstract 6007.
68. Zuo Z, Keck MK, Khattri A et al. Multimodality determination of HPV status in head and neck cancers (HNC) and development of an HPV signature. J Clin Oncol 2013; 31: abstract 6008.
69. Kofler B, Laban S, Busch CJ et al. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2014; 271: 1861-1867.
70. Pajares B, Trigo JM, Toledo MD et al. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer 2013; 13: 26.
71. Quon H, Forastiere AA. Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? J Clin Oncol 2013; 31: 520-522.
72. Gillison ML, Zhang Q, Jordan R et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012; 30: 2102-2111.
73. Rietbergen MM, Brakenhoff RH, Bloemena E et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol 2013; 24: 2740-2745.
74. Marur S. E 1308: a phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). J Clin Oncol 2013; 31: abstract 6005.
75. ClinicalTrials.gov. Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer. 2013; http://clinicaltrials.gov/ct2/show/NCT01302834 (10 July 2014, date last accessed).
76. Radiation Therapy Oncology Group. RTOG 1016 protocol information. http://www. rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1016 2013 (13 August 2014, date last accessed).
77. EU Clinical Trials Register. De-ESCALaTE HPV: determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-0051 65-21/GB 2013 (13 August 2014, date last accessed).
78. Current Controlled Trials. De-ESCALaTE HPV: determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. 2013; http://www.controlled-trials.com/ISRCTN33522080 (10 July 2014, date last accessed).
79. ClincalTrials.gov. The Quarterback trial. 2013; http://clinicaltrials.gov/ct2/show/NCT01706939 (10 July 2014, date last accessed).
80. Clinicaltrials.gov. Post operative adjuvant therapy de-intensification trial for human papillomavirus-related, p16+ oropharynx cancer (ADEPT). 2013; http://clinicaltrials. gov/ct2/show/NCT01687413 (10 July 2014, date last accessed).
81. ClincalTrials.gov. Transoral surgery followed by low-dose or standard-dose radiation therapy with or without chemotherapy in treating patients with HPV positive stage III-IVA oropharyngeal cancer. _rfcollab ClincalTrials.gov
82. Bossi P, Orlandi E, Miceli R et al. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile a tertiary cancer centre series analysis. Ann Oncol 2014; 25(3): 694-699.
83. EORTC. Transgene collaborates with EORTC on phase 2b trial with TG4001 in head & neck cancer. 2013; http://www.eortc.org/news/transgene-collaborates-eortcphase-2b-trial-tg4001-head-neck-cancer (10 July 2014, date last accessed).